Loading stock data…
Geron Corporation (GERN)
$1.51-0.06 (-3.82%)
Market ClosedLast close Sep 8
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Geron Corporation in the Healthcare sector is trading at $1.51 with a market capitalization of $834M. Wall Street consensus targets $4.25 (4 analysts), implying a +181.5% move over the next 12 months. The stock is currently 25% below its 52-week high of $2.01, remaining 4.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +181.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.84M↑ | $48.02M↑ | $47.23M↓ | $49.04M↑ | $39.60M |
| Gross Profit | $50.15M↑ | $46.71M↑ | $46.18M↓ | $47.85M↑ | $38.40M |
| Operating Income | -$236,000↑ | -$8.51M↑ | -$13.89M↓ | -$12.45M↑ | -$16.70M |
| Net Income | -$3.64M↑ | -$28.86M↓ | -$18.43M↓ | -$16.38M↑ | -$19.84M |
Peer Comparison
JNJUNHPFE
Fundamentals
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$833.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.38%
Volume
Today's trading volume
8.30M
Recent News
Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns
Geron stock has recovered over the past year but is still sitting on a steep decline over three years, while the valuation checks currently lean toward the shares looking inexpensive relative to fundamentals. Over the last three years, Geron has delivered a return of about 51% in decline, which signals that long term holders have faced significant capital pressure despite more recent gains. Expectations for Geron's ability to convert its pipeline into sustainable cash flows can support the...
Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative
Why Geron Stock Is Back in Focus After Fresh Guidance Geron (GERN) has drawn fresh attention after issuing 2026 earnings guidance tied to RYTELO net product revenue and releasing second quarter and half year 2026 results on 5 August, including updated revenue and net loss figures. See our latest analysis for Geron. Geron’s latest guidance and earnings update landed alongside a share price of $1.48, with a 7 day share price return of 14.73% and a 1 year total shareholder return of 15.62%. The...
Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?
In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, and a reduced first-half net loss of US$20.32 million, while also filing a US$6.03 million common stock shelf registration for 4,500,000 shares tied to an ESOP. Investors now have an initial full-year 2026 view on RYTELO, with Geron guiding to net product revenue between US$220 million and US$240...
Geron (GERN) Q2 2026 Earnings Call Transcript
RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.
Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Geron Corp (GERN) reports 17% year-over-year net revenue growth, raises full-year guidance, and progresses regulatory discussions for its IMPACT MF trial.